Contact us Demo our platform

LIVE WEBINAR

Metabolon’s Integrated Bioinformatics Platform New Features Release: A Guide To Statistics For Non-Statisticians

Metabolon’s Bioinformatics Platform is a fully integrated solution designed to accelerate research outcomes of metabolomics projects. Users can instantly visualize and represent sample data in meaningful ways that help prove a hypothesis and go deeper, to find novel data insights without prior knowledge or experience of bioinformatics or statistics.

The newly released Statistics Tool in Metabolon’s Integrated Bioinformatics Platform adds to the power and utility of existing features and provides new ways to explore and interpret your data.

The statistics features included within the tool supports further hypothesis testing and enables you to perform advanced data management and enrichment through outlier removal and metadata modification.

In this webinar, Joe Foster, Strategic Product Director, and Heino Heyman, Director of Applied Metabolomics, will demonstrate the features of the new guided statistics tool and provide examples of how outlier removal and metadata modification can improve the impact of other visualization tools and features within the Bioinformatics Platform.

You will learn:

  • How to use the statistics tool to define new analyses

  • Outlier removal best practices and recommendations

  • How to add and modify metadata to gain greater contextual insights from your sample data.

  • How new statistical analyses integrates with the wider Bioinformatics Platform

Program

Time
Presenter
Title/Abstract
11:00 – 11:10 ET
Joe Foster/Dr. Heino Heyman, Ph.D.
Introductions
11:10 – 11:40 ET
Joe Foster
Overview of the new Statistics Tool within Metabolon’s Integrated Bioinformatics Platform, followed by a demonstration of other bioinformatics tools, using new statistical analyses.
11:40 – 11:50 ET
Dr. Heino Heyman, Ph.D.
Routine Solutions for Untargeted and Targeted Metabolomics – From Analyses to Actionable Insights
11:50 – 12:15 ET
Dr. Heino Heyman, Ph.D.
Questions & Answers

Speakers

K
L

Joe Foster

Strategic Products Director

Joe Foster has over 15 years of experience in bioinformatics, spread across genomics, proteomics, lipidomics, and metabolomics. Joe currently serves as Metabolon’s Director of Strategic Products, helping shape the roadmap for the Integrated Bioinformatics Platform and developing Bioinformatics Professional Services that accelerate time to insight with metabolomics and multiomics data.

Prior to joining Metabolon, Joe has held a variety of positions across R&D, customer success, Sales Engineering and Business Development for prominent brands in the Life Sciences industry including, Affymetrix, Thermo Fisher Scientific, and DNAnexus. His career highlights include working with the NHS England Genomic Laboratory Hubs to implement Secure and Scalable Clinical Bioinformatics in the cloud and his work with UK Biobank and Our Future Health to deploy a best-in-class Trusted Research Environment. With a PhD in Bioinformatics from the University of Cambridge and the European Bioinformatics Institute, Joe brings a deep scientific foundation and a practical, results-focused approach to solving complex research challenges.

K
L

Heino Heyman, Ph.D.

Heino HeymanGlobal Field Metabolomics Manager at Metabolon

Dr. Heino M. Heyman is a seasoned Metabolomics professional with an accomplished career spanning over a decade. He embarked on his journey in 2010, utilizing metabolomics to expedite the discovery of active constituents in natural products and to enhance the understanding of resilient crops. In 2015, he joined the Integrative Omics team at Pacific Northwest National Lab, WA, where he broadened the application of metabolomics across diverse sectors, including human, microbial, plant, and soil metabolomics.

Following his postdoctoral studies, he transitioned to the industry, joining Bruker Scientific as a Metabolomics Applications Specialist. He excelled in promoting and demonstrating solutions using sophisticated ion-mobility mass spectrometry instrumentation. In 2020, he joined Metabolon, deepening his involvement in translational science informed by metabolomics. Since 2023, he has been leading a team of metabolomics specialists as Global Metabolomics Application Lead, elevating the metabolomics experience for clients at Metabolon.

REGISTER FOR WEBINAR

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.